For the Inventor, By the Inventor

Enter assignee name

Salt Lake City, UT, United States of America

Nps Pharmaceuticals, Inc.

USPTO Granted Patents = 93

% Expired Patents = 39.8

CIPO Patents = 8

EPO Patents = 8

Trademarks = 7

Forward Citations = 1,305

Loading Chart...

Loading Chart...

103 inventors (with patents filed for the assignee):

Scott T Moe (20 out of 21 patents)

Bradford C Van Wagenen (19 out of 25 patents)

Manuel F Balandrin (18 out of 22 patents)

4. Karen J Krapcho (14 out of 14 patents)

5. Eric G DelMar (14 out of 17 patents)

6. Robert M Kral, Jr (12 out of 12 patents)

7. Thomas M Stormann (11 out of 14 patents)

8. Bradford C VanWagenen (11 out of 11 patents)

9. Robert M Barmore (10 out of 12 patents)

10. Alan L Mueller (9 out of 10 patents)

11. Janice H Johnson (9 out of 9 patents)

12. Lance G Hammerland (8 out of 8 patents)

13. Thomas B Marriott (7 out of 25 patents)

14. Linda D Artman (7 out of 8 patents)

15. Daryl Lynn Smith (6 out of 13 patents)

Core Competencies:

GLP-2 Analog

Calcium Receptor Compounds

CNS Disorders

Bone Resorption Diseases

Insecticidal Peptides

Metabotropic Glutamate Receptor

Short Bowel Syndrome

Anxiety Disorders

Sustained-Release Formulations

Fluorinated Compounds

Heteropolycyclic Compounds

G-Protein Fusion Receptors

93 patents: Sort by Forward Citations

1. 9782455 - Solid phase synthesis of h(Gly2)GLP-2 (2017-10-10),

2. 9555079 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-31),

3. 9545435 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-17),

4. 9545434 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-17),

5. 9539310 - Treatment of short bowel syndrome patients with colon-in-continuity (2017-01-10),

6. 9060992 - Treatment of short bowel syndrome patients with colon-in-continuity (2015-06-23),

7. 8980567 - Ex vivo method for determining potential GLP-2 receptor modulators (2015-03-17),

8. 8933039 - Glucagon-like peptide-2 analogs (2015-01-13),

9. 8765674 - Methods useful in the treatment of bone resorption diseases (2014-07-01),

10. 8592553 - Cloned glucagon-like peptide-2 receptors (2013-11-26),

11. 8481276 - Ex vivo method for determining potential GLP-2 receptor modulators (2013-07-09),

12. 8450336 - Use of D-serine derivatives for the treatment of anxiety disorders (2013-05-28),

13. 8257983 - Ex vivo method for determining potential GLP-2 receptor modulators (2012-09-04),

14. 8153588 - Methods useful in the treatment of bone resorption diseases (2012-04-10),

15. 8148508 - Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides (2012-04-03),

NPS Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes innovative medicines for patients with rare diseases. They focus on diseases with high unmet medical needs and strive to improve the lives of those affected. NPS Pharmaceuticals aims to provide effective and safe treatment options through their research and development efforts. With a commitment to making a difference, they work towards addressing the challenges faced by patients and their families.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

93 Patents

#12 in Salt Lake City, UT

#40 in Utah

#4,023 in US

#8,271 in the World

Salt Lake City, UT, United States of America

Nps Pharmaceuticals, Inc.

Forward Citations = 1,305

103 inventors:

Scott T Moe (20 out of 21 patents)

Bradford C Van Wagenen (19 out of 25 patents)

Manuel F Balandrin (18 out of 22 patents)

4. Karen J Krapcho (14 out of 14 patents)

5. Eric G DelMar (14 out of 17 patents)

Please report any incorrect information to [email protected]

Loading…